Christophe Bonny PhD

Dr Bonny has over 20 years’ experience in the field of molecular biology and signalling pathways, 15 years in the field of hit identification to candidate selection, has authored over 100 scientific publications and is an inventor on several patents. Dr Bonny discovered XG-102/AM-111 and XG-104, the two first clinical stage intracellular peptides currently in Phases 3 and 2 trials for diverse inflammatory conditions, respectively. These intracellular peptidic inhibitors of the JNK protein formed the basis for the creation of the biotechnology company Xigen SA in 2003. In 2005, he received the Pfizer Research Prize for this discovery. Dr Bonny was CSO of Xigen SA and also served as its President, and then was CSO at Bicycle Therapeutics. The cumulated investments in the companies Dr Bonny served as CSO is over $110 M. He also held the position of Head of Research of the Medical Genetics Unit at the University Hospital of Lausanne (Centre Hospitalier Universitaire Vaudois, Switzerland) and a prior to this was a Research Fellow at Northwestern University (US). Dr Bonny obtained a PhD from the University of Neuchâtel (Switzerland), and completed a business and entrepreneurship program at Babson College (US).